Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders

Expert Opinion on Drug Discovery

Volumn 7, Issue 3, 2012, Pages 261-280

  Célanire, Sylvain ^a   Campo, Brice ^a  

^a ADDEX PHARMACEUTICALS   (Switzerland)

Author keywords

ADX88178; Central nervous system; Class C GPCRs; Glutamate; l DOPA; LSP4 2022; Metabotropic glutamate receptor 4; Neuroinflammation; Orthosteric agonist; Parkinson's disease; PHCCC; Positive allosteric modulator; Potentiator; Preladenant; VU0364770

Indexed keywords

1 AMINO 2 PHOSPHONOMETHYLCYCLOPROPANECARBOXYLIC ACID; 1 AMINOCYCLOPENTANE 1,3,4 TRICARBOXYLIC ACID; 2 AMINO 4 PHOSPHONOBUTYRIC ACID; ADX 36443; ADX 62997; ADX 63456; ADX 88178; ALPHA METHYLSERINE O PHOSPHATE; AMG 884936; CYCLOPROPANECARBOXYLIC ACID DERIVATIVE; DT 1; DT 2; GLUTAMIC ACID DERIVATIVE; LEVODOPA; LSP1 1011; LSP1 2093; LSP1 2111; LSP1 3081; LSP4 2022; LUAF 21934; METABOTROPIC RECEPTOR 4; METABOTROPIC RECEPTOR AGONIST; N PHENYL 7 (HYDROXYIMINO)CYCLOPROPA[B]CHROMEN 1A CARBOXAMIDE; PHOSPHOROTHIOIC ACID DERIVATIVE; PICOLINAMIDE; TCN 238; UNCLASSIFIED DRUG; UNINDEXED DRUG; VU 0003423; VU 015540; VU 0155401; VU 0359516; VU 0361737; VU 0364770; VU 0448383; VU 400195;

ALLOSTERISM; ANXIETY DISORDER; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICAL STRUCTURE; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; EPILEPSY; HUMAN; INFLAMMATION; METABOLIC SYNDROME X; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NEUROMODULATION; NEUROPATHIC PAIN; NONHUMAN; PAIN; PARKINSON DISEASE; POSITIVE SYNDROME; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; ANIMALS; BIOLOGICAL AVAILABILITY; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID AGONISTS; HUMANS; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84857537058     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.660914     Document Type: Review

References (113)

1. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997;37:205-37 (Pubitemid 27238875)
2. Nakanishi S, Nakajima Y, Masu M, et al. Glutamate receptors: brain function and signal transduction. Brain Res Brain Res Rev 1998;26:230-5 (Pubitemid 28318078)
3. Schoepp DD, Jane DE, Monn JA. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999;38:1431-76 (Pubitemid 29457728)
4. Valenti O, Marino MJ, Wittmann M, et al. Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. J Neurosci 2003;23:7218-26 (Pubitemid 36975886)
5. Marino MJ, Hess JF, Liverton N. Targeting the metabotropic glutamate receptor mGluR4 for the treatment of diseases of the central nervous system. Curr Top Med Chem 2005;5:885-95 (Pubitemid 41269561)
6. Lavreysen H, Dautzenberg FM. Therapeutic potential of group III metabotropic glutamate receptors. Curr Med Chem 2008;15:671-84 (Pubitemid 351516803)
7. Johansen PA, Chase LA, Sinor AD, et al. Type 4a metabotropic glutamate receptor: identification of new potent agonists and differentiation from the L-(+)-2-Amino-4-phosphonobutanoic acid-sensitive receptor in the lateral perforant pathway in rats. Mol Pharmacol 1995;48:140-9
8. Trombley PQ, Westbrook GL. L-AP4 inhibits calcium currents and synaptic transmission via a G-protein-coupled glutamate receptor. J Neurosci 1992;12:2043-50
9. MacInnes N, Messenger MJ, Duty S. Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat. Br J Pharmacol 2004;141:15-22 (Pubitemid 38241159)
10. Selvam C, Goudet C, Oueslati N, et al. L-(+)-2-Amino-4- thiophosphonobutyric acid (L-thioAP4), a new potent agonist of group III metabotropic glutamate receptors: increased distal acidity affords enhanced potency. J Med Chem 2007;50:4656-64 (Pubitemid 47469678)
11. Acher FC, Tellier FJ, Azerad R, et al. Synthesis and pharmacological characterization of aminocyclopentanetricarboxylic acids: new tools to discriminate between metabotropic glutamate receptor subtypes. J Med Chem 1997;40:3119-29 (Pubitemid 27391544)
12. Institut National des Sciences Appliquees de Rouen (INSA). Preparation of fluorinated cyclopropane analogs of glutamic acid as mGluR4 modulators useful in the treatment of neurological diseases. WO2011009947; 2011
13. Sibille P, Lopez S, Brabet I, et al. Synthesis and biological evaluation of 1-Amino-2- phosphonomethylcyclopropanecarboxylic acids, new group III metabotropic glutamate receptor agonists. J Med Chem 2007;50:3585-95 (Pubitemid 47195465)
14. Triballeau N, Acher F, Brabet I, et al. Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype. 4. J Med Chem 2005;48:2534-47. (Pubitemid 40520517)
15. Selvam C, Oueslati N, Lemasson IA, et al. A virtual screening hit reveals new possibilities for developing group III metabotropic glutamate receptor agonists. J Med Chem 2010;53:2797-813
16. Centre National De La Recherche Scientifique. Preparation of hypophosphorous acid derivatives, particularly substituted hypophosphorous acid-containing glycine derivatives, as agonists and antagonists of metabotropic glutamate receptors, especially mGluR4. WO2007052169; 2007
17. Hampson DR, Huang XP, Pekhletski R, et al. Probing the ligand-binding domain of the mGluR4 subtype of metabotropic glutamate receptor. J Biol Chem 1999;274:33488-95 (Pubitemid 129511657)
18. Acher FC, Selvam C, Pin JP, et al. A critical pocket close to the glutamate binding site of mGlu receptors opens new possibilities for agonist design. Neuropharmacology 2011;60:102-7
19. Goudet C, Vilar B, Courtiol T, et al. A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential. FASEB J 2012;published online on January 5, 2012; doi: 10.1096/fj.11-195941.
20. Cuomo D, Martella G, Barabino E, et al. Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment. J Neurochem 2009;109:1096-105
21. Burford NT, Watson J, Bertekap R, Alt A. Strategies for the identification of allosteric modulators of G-protein-coupled receptors. Biochem Pharmacol 2011;81:691-702
22. Bridges TM, Lindsley CW. G-Protein-Coupled receptors: from classical modes of modulation to allosteric mechanisms. Chem Biol 2008;19(3):530-41
23. Rocheville M, Garland SL. An industrial perspective on positive allosteric modulation as a means to discover safe and selective drugs. Drug Discov Today 2010;7:e87-94
24. Maj M, Bruno V, Dragic Z, et al. (-)- PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology 2003;45:895-906 (Pubitemid 37297915)
25. Marino MJ, Williams DL Jr, O'Brien JA, et al. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci USA 2003;100:13668-73 (Pubitemid 37444797)
26. Williams R, Zhou Y, Niswender CM, et al. Re-exploration of the PHCCC scaffold: discovery of improved positive allosteric modulators of mGluR4. ACS Chem Neurosci 2010;1:411-19
27. Domain Therapeutics, Prestwick Chemical. Preparation of novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors. WO2011051478; 2011
28. Niswender CM, Johnson KA, Weaver CD, et al. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor. 4. Mol Pharmacol 2008;74:1345-58.
29. Doller D, Hong SP, Uberti MA, et al. LuAF219934, a brain penetrant mGluR4 receptor positive allosteric modulator tool compound [Poster 655.28]. Society for Neuroscience Meeting; San Diego; 2011
30. Christov C, Gonzalez-Bulnes P, Malhaire F, et al. Integrated synthetic, pharmacological, and computational investigation of cis-2-(3,5- dichlorophenylcarbamoyl) cyclohexanecarboxylic acid enantiomers as positive allosteric modulators of metabotropic glutamate receptor subtype. 4. Chem Med Chem 2011;6:131-40.
31. East SP, Bamford S, Dietz MG, et al. An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction. Bioorg Med Chem Lett 2010;20:4901-5
32. Mathiesen JP, Svenden N, Braumer-Osborne H, et al. Positive allosteric modulation of human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol 2003;138:1026-30
33. Robichaud AJ, Engers DW, Lindsley CW, Hopkins CR. Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics. ACS Chem Neurosci 2011;2:433-49
34. Reynolds IJ. Metabotropic glutamate receptors as therapeutic targets in Parkinson's Disease. 6th International Meeting on Metabotropic Glutamate Receptors; Taormina; 2008
35. Merck & Co. Preparation of phthalimidephenylpyridinecarboxamide derivatives for use as metabotropic glutamate R4 modulators. WO2010033349; 2010
36. Merck & Co. Sulfonamide derivatives as mGluR4 receptor ligands. WO2010033350; 2010
37. Addex Pharma S.A. Preparation of amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors. WO2009010454; 2009
38. Engers DW, Niswender CM, Weaver CD, et al. Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). J Med Chem 2009;52:4115-18
39. Jones CK, Bubser M, Thompson AD, et al. The mGlu4 positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine A2A antagonist in preclinical rodent models of Parkinson's disease. J Pharmacol Exp Ther 2012;340:404-21
40. Engers DW, Field JR, Le U, et al. Discovery, synthesis, and structure-activity relationship development of a series of N-(4- acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)) with CNS exposure in rats. J Med Chem 2011;54:1106-10
41. Engers DW, Gentry PR, Williams R, et al. Synthesis and SAR of novel, 4- (phenylsulfamoyl)phenylacetamide mGlu4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS). Bioorg Med Chem Lett 2010;20:5175-8
42. Jones CK, Engers DW, Thompson AD, et al. Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2, 5-dioxopyrrolidin-1-yl) phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu4) with oral efficacy in an antiparkinsonian animal model. J Med Chem 2011;54:7639-47
43. Vanderbilt University. Imidazolidinone derivatives and related compounds as mGluR4 allosteric potentiators and their preparation, compositions, and methods of treating neurological dysfunction. WO2011029104; 2011
44. Vanderbilt University. Metabotropic glutamate receptor subtype 4 allosteric potentiator compositions and methods of treating neurological dysfunction. WO2011050316; 2011
45. Vanderbilt University. Heterocyclic sulfone metabotropic glutamate receptor subtype 4 allosteric potentiators and compositions, and methods of treating neurological dysfunction. WO2011143466; 2011
46. Vanderbilt University. Aryl and heteroaryl sulfones as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction. WO2011057208; 2011
47. Vanderbilt University. Substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mGluR4 potentiators. WO2011011722; 2011
48. Vanderbilt University. Benzisoxazoles and azabenzisoxazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction. WO2011100614; 2011
49. Celanire S, Bolea C, Bruckner S, et al. Discovery and characterization of novel metabotropic glutamate receptor 4 (mGluR4) allosteric potentiators [abstract 24]. Taormina: 7th International Meeting on Metabotropic Glutamate Receptors (October 2-7, 2011). Curr Neuropharmacol 2011;9(Suppl 1):8
50. Addex Pharma S.A. Preparation of novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors. WO2009010455; 2009
51. Addex Pharma S.A. Novel thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors and preparation. WO2010079239; 2010
52. Addex Pharma S.A. Preparation of 4-amino-thiazoles and 3-amino- 1,2,4-thiadiazoles and their use as allosteric modulators of metabotropic glutamate receptors. WO2011086163; 2011
53. Addex Pharma S.A. Novel pyrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors and their preparation. WO2011010222; 2011
54. Addex Pharma S.A. Preparation of heteroaryldihydrothiazoloindazoleamine derivatives and analogs as metabotropic glutamate receptors modulators. WO2010079238; 2010
55. Hong SP, Liu KG, Ma G, et al. Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem 2011;54:5070-81
56. Drolet RE, Tugusheva K, Liverton N, et al. Binding property characterization of a novel mGluR4 positive allosteric modulator [Poster 553.12]. Society for Neuroscience meeting; Washington; 2011
57. Utley T, Haddenham D, Salovich JM, et al. Synthesis and SAR of a novel metabotropic glutamate receptor 4 (mGlu4) antagonist: unexpected 'molecular switch' from a closely related mGlu4 positive allosteric modulator. Bioorg Med Chem Lett 2011;21:6955-9
58. Marino MJ, Awad H, Poisik O, et al. Localization and physiological roles of metabotropic glutamate receptors in the direct and indirect pathways of the basal ganglia. Amino Acids 2002;23:185-91
59. Bradley SR, Standaert DG, Rhodes KJ, et al. Immunohistochemical Localization of Subtype 4a metabotropic glutamate receptors in the rat and mouse Basal Ganglia. J Comp Neurol 1999;407:33-46 (Pubitemid 29161991)
60. Meissner WG, Frasier M, Gasser T, et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov 2011;10:377-93
61. Smith Y, Wichmann T, Factor SA, Delong MR. Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology 2011;37:213-46
62. Salamone JD. Facing Dyskinesia in Parkinson's disease: nondopaminergic approaches. Drugs Future 2010;35:567-73
63. Lindsley CW, Niswender CM, Engers DW, Hopkins CR. Recent progress in the development of mGluR4 positive allosteric modulators for the treatment of Parkinson's disease. Curr Top Med Chem 2009;9:949-63
64. Duty S. Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease. Br J Pharmacol 2010;161:271-87
65. Sibille P, Lopez S, Brabet I, et al. Synthesis and biological evaluation of 1-amino-2- phosphonomethylcyclopropanecarboxylic acids, new group III metabotropic glutamate receptor agonists. J Med Chem 2007;50:3585-95 (Pubitemid 47195465)
66. Konieczny J, Wardas J, Kuter K, et al. The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane- 1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats. Neuroscience 2007;145:611-20 (Pubitemid 46341652)
67. Lopez S, Turle-Lorenzo N, Acher F, et al. Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease. J Neurosci 2007;27:6701-11 (Pubitemid 46983444)
68. Conn PJ, Battaglia G, Marino MJ, Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 2005;6:787-98 (Pubitemid 41679241)
69. Beurrier C, Lopez S, Revy D, et al. Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J 2009;23:3619-28
70. Deltheil T, Turle-Lorenzo N, Amalric M. Orthosteric group III mGlu receptor agonist for Parkinson's disease treatment: symptomatic and neurochemical action on pallidal synaptic transmission [abstract 40]. Taormina: 7th International Meeting on Metabotropic Glutamate Receptors (October 2-7, 2011). Curr Neuropharmacol 2011;9(Suppl 1):8
71. Reynolds IJ. Novel mGluR4 Positive Allosteric Modulators for Parkinson's Disease. World Pharma Congress - Targeting Parkinson's Disease; Philadelphia: 2011
72. Campo B. Novel metabotropic glutamate receptor 4 (mGluR4) allosteric potentiators for the treatment of Parkinson's disease and anxiety [abstract 22]. Taormina: 7th International Meeting on Metabotropic Glutamate Receptors (October 2-7, 2011). Curr Neuropharmacol 2011;9(Suppl 1):8
73. Bennouar KE, Uberti MA, Melon C, et al. Synergy between L-DOPA and a novel positive metabotropic glutamate receptor 4: implication for Parkinson's disease treatment and dyskinesia. Neuropharmacology 2012; submitted
74. Niswender C. The Development of Positive Allosteric Modulators of mGluR4 for the Treatment of Parkinson's Disease. Allosteric Modulator Drug Discovery Congress; San Diego: 2010
75. Shanker YG. Identification and Characterization of Allosteric Modulators of mGluR4 for the Treatment of Parkinson's Disease. Discovery on Target meeting - Targeting Diverse Pathways for Tomorrow's Therapeutics; Boston: 2010
76. Valenti O, Mannaioni G, Seabrook GR, et al. Group III metabotropic glutamate-receptor-mediated modulation of excitatory transmission in rodent substantia nigra pars compacta dopamine neurons. J Pharmacol Exp Ther 2005;313:1296-304 (Pubitemid 40727035)
77. Vernon AC, Zbarsky V, Datla KP, et al. Selective activation of group III metabotropic glutamate receptors by L-(+)-2-amino-4-phosphonobutryic acid protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J Pharmacol Exp Ther 2007;320:397-409 (Pubitemid 46025754)
78. Vernon AC, Palmer S, Datla KP, et al. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. Eur J Neurosci 2005;22:1799-806 (Pubitemid 41482969)
79. Battaglia G, Busceti CL, Molinaro G, et al. Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-Methyl-4-Phenyl-1,2,3,6- Tetrahydropyridine. J Neurosci 2006;26:7222-9
80. Prediger RD, Matheus FC, Schwarzbold ML, et al. Anxiety in Parkinson's disease: a critical review of experimental and clinical studies. Neuropharmacology 2012;62:115-24
81. Palucha A, Pilc A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther 2007;115:116-47 (Pubitemid 46992810)
82. Stachowicz K, Klodzinska A, Palucha-Poniewiera A, et al. The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems. Neuropharmacology 2009;57:227-34
83. Wieronska JM, Stachowicz K, Palucha-Poniewiera A, et al. Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems. Neuropharmacology 2010;59:627-34
84. Campo B. Validating the Role of mGluR4 Receptors in the Physiopathology of Anxiety using a Selective mGluR4 Positive Allosteric Modulator. Allosteric Modulator Drug Discovery Congress; San Diego: 2010
85. Klak K, Palucha A, Branski P, et al. Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats. Amino Acids 2007;32:169-72 (Pubitemid 46198739)
86. Palucha A, Tatarczynska E, Branski P, et al. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology 2004;46:151-9 (Pubitemid 37532823)
87. Scrivo R, Vasile M, Bartosiewicz I, Valesini G. Inflammation as "common soil" of the multifactorial diseases. Autoimmun Rev 2011;10:369-74
88. Nicoletti F, Bruno V, Copani A, et al. Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci 1996;19:267-71 (Pubitemid 26000672)
89. Taylor DL, Diemel LT, Pocock JM. Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity. J Neurosci 2003;23:2150-60 (Pubitemid 36368903)
90. Fallarino F, Volpi C, Fazio F, et al. Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nat Med 2010;16:897-902
91. Neugebauer V. Glutamate receptor ligands. Handb Exp Pharmacol 2007;177:217-49
92. Goudet C, Magnaghi V, Landry M, et al. Metabotropic receptors for glutamate and GABA in pain. Brain Res Rev 2009;60:43-56
93. Goudet C, Chapuy E, Allaoui A, et al. Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain. Pain 2008;137:112-24 (Pubitemid 351802243)
94. Wang H, Jiang W, Yang R, Li Y. Spinal metabotropic glutamate receptor 4 is involved in neuropathic pain. Neuroreport 2011;22:244-8
95. Kinon BJ. Clinical aspects of modulation of glutamatergic mechanisms in the treatment of Schizophrenia. Drugs Future 2010;35:557-66
96. Palucha-Poniewiera A, Klodzinska A, Stachowicz K, et al. Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents. Neuropharmacology 2008;55:517-24
97. Wieronska JM, Stachowicz K, Acher F, et al. Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia. Psychopharmacology 2011;published on line 28 September 2011; doi: 10.1007/s00213-011-2502-2
98. Muhle H, von SS, Gaus V, et al. Role of GRM4 in idiopathic generalized epilepsies analysed by genetic association and sequence analysis. Epilepsy Res 2010;89:319-26
99. Ngomba RT, Ferraguti F, Badura A, et al. Positive allosteric modulation of metabotropic glutamate 4 (mGlu4) receptors enhances spontaneous and evoked absence seizures. Neuropharmacology 2008;54:344-54
100. Watanabe Y, Kaida Y, Fukuhara S, et al. Participation of metabotropic glutamate receptors in pentetrazol-induced kindled seizure. Epilepsia 2011;52:140-50
101. Moyanova SG, Mastroiacovo F, Kortenska LV, et al. Protective role for type 4 metabotropic glutamate receptors against ischemic brain damage. J Cereb Blood Flow Metab 2011;31:1107-18
102. de Groot J, Sontheimer H. Glutamate and the biology of gliomas. Glia 2011;59:1181-9
103. Brocke KS, Staufner C, Luksch H, et al. Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol Ther 2010;9:455-68
104. Pissimissis N, Papageorgiou E, Lembessis P, et al. The glutamatergic system expression in human PC-3 and LNCaP prostate cancer cells. Anticancer Res 2009;29:371-7
105. Iacovelli L, Arcella A, Battaglia G, et al. Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas. J Neurosci 2006;26:8388-97 (Pubitemid 44309853)
106. Uehara S, Muroyama A, Echigo N, et al. Metabotropic glutamate receptor type 4 is involved in autoinhibitory cascade for glucagon secretion by alpha-cells of islet of Langerhans. Diabetes 2004;53:998-1006 (Pubitemid 38436612)
107. Tong Q, Ouedraogo R. Kirchgessner Al. Localization and function of group III metabotropic glutamate receptors in rat pancreatic islets. Am J Physiol Endocrinol Metab 2002;282(6):E1324-33 (Pubitemid 34654702)
108. Tanabe Y, Masu M, Ishii T, et al. A Family of metabotropic glutamate receptors. Neuron 1992;8:169-79
109. Flor PJ, Lukic S, Ruegg D, et al. Molecular cloning, functional expression and pharmacological characterization of the human metabotropic glutamate receptor type. 4. Neuropharmacology 1995;34:149-55
110. Marshall FH. Is the GABA B heterodimer a good drug target? J Mol Neurosci 2005;26:169-76
111. Wichmann T, DeLong MR. Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol 1996;6:751-8 (Pubitemid 27052915)
112. Pekhletski R, Gerlai R, Overstreet LS, et al. Impaired cerebellar synaptic plasticity and motor performance in mice lacking the mGluR4 subtype of metabotropic glutamate receptor. J Neurosci 1996;16:6364-73 (Pubitemid 26337360)
113. Makoff A, Lelchuk R, Oxer M, et al. Molecular characterization and localization of human metabotropic glutamate receptor type.4. Brain Res Mol Brain Res 1996;37:239-48 (Pubitemid 26147996)